Senior Fellow, Group Director

Pascal Chanu

Oncologie (tumeur solide et hème), maladie fibrotique, atrophie géographique

“Ma principale motivation est d’avoir un impact sur le développement de médicaments en utilisant des méthodes fondées sur des modèles.”

Rôle à l’Institut Roche et parcours professionnel :

J’ai rejoint l’Institut Roche en 2016 pour soutenir le département de pharmacologie clinique de gRED (Genentech Research and Early Development). Je suis actuellement directeur de groupe dans le groupe M&S. Je supervise principalement des projets en oncologie et dans les maladies fibrotiques.
Je suis pharmacométricien et pharmacologue clinique avec plus de vingt ans d’expérience en M&S et en développement de médicaments dans les hôpitaux (trois ans), dans l’industrie pharmaceutique (plus de onze ans, principalement dans le groupe Roche) et dans le conseil (plus de sept ans).

Objectif à l’Institut Roche :

J’assure la supervision scientifique M&S pour la moitié du portefeuille gRED Oncologie et dans le domaine des maladies fibrotiques.

Je développe actuellement des modèles de maladies pour le myélome multiple et l’atrophie géographique et je supervise la modélisation des maladies dans les domaines oncologiques et non-oncologiques.

Activités interfonctionnelles : je supervise également une initiative pour l’utilisation de données du monde réel (Real-World Data : RWD) en pharmacologie clinique. Je préside l’équipe interfonctionnelle d’extrapolation pédiatrique.

  1. Li CC, et al. (2025) “A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.” Clin Pharmacol Ther. 117(2):465-474.
  2. Chan P, et al. (2025) “Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.” CPT Pharmacometrics Syst Pharmacol. 14(4):726-737.
  3. Marchand M, et al. (2024) “Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches.” CPT Pharmacometrics Syst Pharmacol. 13(6):1017-1028.
  4. Tang AS,et al.(2025) “Use of Real-World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug-Drug Interaction Risk in Target Patient Populations.” Clin Pharmacol Ther. 1.
  5. Vora B, et al. (2024) “Expanding the use of real-world data through the development of user-friendly tools to support drug development: Example of an organ impairment dashboard.” Pharmacol Res Perspect. 12(4):e1239.
  6. Zhu R, et al. (2023)”Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.” Clin Pharmacol Ther.114(4):751-767.
  7. Bruno R, et al. (2023) “Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.” Br J Cancer. 129(9):1383-1388.
  8. Jamalian S, et al. (2023) “Modeling Alzheimer’s disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.” CPT Pharmacometrics Syst Pharmacol. 12(7):1029-1042.
  9. Bruno R, et al. (2023) “Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.” Clin Cancer Res. 29(6):1047-1055.
  10. Bruno R, et al. (2023) ”Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.” Clin Cancer Res.29(20):4314.
  11. Julian C., Machado R.J.M., Girish S., Chanu P., Heinzmann D., Harbron C., Gershon A., Pfeiffer S.M., Zou W., Quarmby V., Zhang Q., Chen Y. Real-world data prognostic model of overall survival in patientswith advanced NSCLC receiving anti-PD-1/PD-L1 immunecheckpoint inhibitors as second-line monotherapy. Cancer Reports, 2022;e1578. doi:10.1002/cnr2.1578
  12. Chanu P., Musib L., Wang X., Cheeti S., Girish S., Bruno R., Lu T., Reddy J., Jin J.Y., Caro I. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation. Journal of Investigative Dermatology, 141, 930-933, 2021.
  13. Felip E., Burotto M., Zvirbule Z., Herraez-Baranda L.A., Chanu P., Kshirsagar S., Maiya V., Chan P., Pozzi E. Marchand M., Monchalin M., Tanaka K., Tosti N., Wang B., Restuccia E. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer. Clinical Pharmacology in Drug Development, 10, 1142-1155, 2021.
  14. Yoshida K., Wilkins J., Winkler J., Wade J.R., Kotani N., Wang N., Sane R., Chanu P. Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. Journal of Clinical Pharmacology, 61, 1579-1591, 2021.
  15. Chanu P., Schaefer F., Warady B.A., Schmitt C.PC, Reigner B., Schnetzler G., Reigner S.M., Eisner M., Weichert A., Frey N. Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. British Journal of Clinical Pharmacology 86, 801-811, 2020.
  16. Lu D., Lu T., Gibiansky L., Li X. Li C., Agarwal P., Shemesh C.S., Shi R., Dere R.C., Hirata J., Miles D., Chanu P., Girish S., Jin J.Y.Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients with Non- Hodgkin Lymphoma. Clinical Pharmacology Therapeutics: Pharmacometry and System Pharmacology 9, 48-59, 2020.
  17. Lu T., Gibiansky L., Li X. Li C., Shi R., Agarwal P., Hirata J., Miles D., Chanu P., Girish S., Jin J.Y. Lu D. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma, 61, 2905-2914, 2020.
  18. Lu D., Lu T., Shi R., Gibiansky L., Agarwal P., Shemesh C.S., Dere R.C., Ogbu U, Hirata J., Chanu P., Girish S., Jin J.Y., Li C., Miles D. Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. Pharmaceutical Research, https://doi.org/10.1007/s11095-020-02933-6, published online December 1, 2020.
  19. Shemesh C.S., Chanu P., Jamsen K., Wada R., Rossato G., Donaldson F., Garg A., Winter H., Ruppel J., Wang X., Bruno R., Jin J.Y.,Girish S. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer, doi: 10.1186/s40425-019-0791-x., published online November 21, 2019.
  20. Chanu P., Gao X., Bruno R., Claret L., Harnisch L. A modeling and simulation- based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. Journal of Pharmacokinetics and Pharmacodynamics 46, 499-509, 2019.
  21. Han K., Chanu P., Jonsson F., Winter H., Bruno R., Jin J., Stroh M. Exposure- Response and Tumor Growth Inhibition analyses of the monovalent anti-c-MET antibody onartuzumab (MetMAb) in the second- and third-line Non-Small Cell Lung Cancer. AAPS Journal 19, 527-533, 2017.
  22. Claret L., Zheng J., Mercier F., Chanu P., Chen Y., Rosbrook B., Yazdi P., Milligan P.A., Bruno R. Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer Chemotherapy and Pharmacology, 78, 605-610, 2016.
  23. Bruno R., Lindbom L., Schaedeli Stark F., Chanu P., Gilberg F., Frey N., Claret L. Simulations to assess Phase II non-inferiority trials of different doses of capecitabine in combination with docetaxel for metastatic breast cancer. Clinical Pharmacology Therapeutics: Pharmacometry and System Pharmacology, 1, e19, doi:10.1038/psp.2012.20, published online 26 December 2012.
  24. Chanu P., Gieschke R., Charoin J.E., Pannier A., Reigner B. – Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. Journal of Clinical Pharmacology, 50(5), 507-520, 2010.
  25. Snoeck E., Chanu P., Lavielle M., Jacqmin P., Jonsson E.N., Jorga K., Goggin T., Grippo J., Jumbe N.L., Frey N. – A comprehensive hepatitis C viral kinetic model explaining cure. Clinical Pharmacology Therapeutics, 87(6), 706-713, 2010. AAPS (American Association of Pharmaceutical Scientists) Outstanding Manuscript Award in Modeling and Simulation.
  26. Rayner C.R., Chanu P., Gieschke R., Boak L.M., Jonsson E.N. – Population pharmacokinetics of oseltamivir when coadministered with probenecid. Journal of Clinical Pharmacology, 48(8), 935-947, 2008.
Plus de publications